WO2003050502A3 - Identification et caracterisation prospectives des cellules souches cancereuses du sein - Google Patents

Identification et caracterisation prospectives des cellules souches cancereuses du sein Download PDF

Info

Publication number
WO2003050502A3
WO2003050502A3 PCT/US2002/039191 US0239191W WO03050502A3 WO 2003050502 A3 WO2003050502 A3 WO 2003050502A3 US 0239191 W US0239191 W US 0239191W WO 03050502 A3 WO03050502 A3 WO 03050502A3
Authority
WO
WIPO (PCT)
Prior art keywords
tumorigenic
cells
cancer cells
tumors
populations
Prior art date
Application number
PCT/US2002/039191
Other languages
English (en)
Other versions
WO2003050502A2 (fr
WO2003050502A9 (fr
Inventor
Michael F Clarke
Max S Wicha
Mohammad Al-Hajj
Original Assignee
Univ Michigan
Michael F Clarke
Max S Wicha
Mohammad Al-Hajj
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to AU2002364537A priority Critical patent/AU2002364537A1/en
Priority to US10/497,791 priority patent/US20050089518A1/en
Priority to EP02799914A priority patent/EP1461023A4/fr
Priority to CA002469204A priority patent/CA2469204A1/fr
Priority to JP2003551505A priority patent/JP2005511754A/ja
Application filed by Univ Michigan, Michael F Clarke, Max S Wicha, Mohammad Al-Hajj filed Critical Univ Michigan
Publication of WO2003050502A2 publication Critical patent/WO2003050502A2/fr
Publication of WO2003050502A3 publication Critical patent/WO2003050502A3/fr
Publication of WO2003050502A9 publication Critical patent/WO2003050502A9/fr
Priority to US11/607,780 priority patent/US7754206B2/en
Priority to US11/651,214 priority patent/US20090004205A1/en
Priority to US12/758,540 priority patent/US20110033481A1/en
Priority to US13/563,884 priority patent/US20120295350A1/en
Priority to US13/795,381 priority patent/US9089556B2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6891—Pre-targeting systems involving an antibody for targeting specific cells
    • A61K47/6897—Pre-targeting systems with two or three steps using antibody conjugates; Ligand-antiligand therapies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6901—Conjugates being cells, cell fragments, viruses, ghosts, red blood cells or viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3015—Breast
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0693—Tumour cells; Cancer cells
    • C12N5/0695—Stem cells; Progenitor cells; Precursor cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Nanotechnology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Developmental Biology & Embryology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medical Informatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)

Abstract

Les tumeurs du sein chez l'être humain contiennent des cellules cancéreuses hétérogènes. A l'aide d'un modèle de xénogreffe animale dans laquelle on a fait croître des cellules cancéreuses du sein chez des souris immunodéprimées, il a été découvert que seule une petite minorité de cellules cancéreuses du sein étaient capables de former de nouvelles tumeurs. La capacité à former de nouvelles tumeurs n'était pas une propriété stochastique, mais certaines populations de cellules cancéreuses étaient dépourvues de cette capacité tandis que d'autres en étaient pourvues. Il a été possible de distinguer les cellules tumorigènes des cellules cancéreuses non tumorigènes, sur la base de l'expression de marqueurs de surface. Les cellules tumorigènes ont été prospectivement identifiées et isolées en tant que LIGNEE-CD44+CD24-/lo. Seules une centaine de cellules issues de cette population ont pu former des tumeurs dans le modèle de xénogreffe animale, alors que des dizaines de milliers de cellules issues de populations non tumorigènes n'ont pas eu cette capacité. Les cellules tumorigènes ont pu subir des passages en série, chaque passage générant de nouvelles tumeurs contenant un nombre plus important de cellules tumorigènes LIGNEE-CD44+CD24-/lo et des populations mélangées phénotypiquement de cellules cancéreuses non tumorigènes. Cette particularité rappelle l'aptitude des cellules souches normales à s'auto-renouveler et à se différencier. L'expression de cibles thérapeutiques potentielles s'est également avérée différente entre les populations tumorigènes et non tumorigènes. L'activation des gènes NOTCH a facilité la survie des cellules tumorigènes, et un anticorps bloquant dirigé contre NOTCH4 a induit l'apoptose de cellules cancéreuses du sein.
PCT/US2002/039191 2000-08-03 2002-12-06 Identification et caracterisation prospectives des cellules souches cancereuses du sein WO2003050502A2 (fr)

Priority Applications (10)

Application Number Priority Date Filing Date Title
AU2002364537A AU2002364537A1 (en) 2001-12-07 2002-12-06 Prospective identification and characterization of breast cancer stem cells
US10/497,791 US20050089518A1 (en) 2001-12-07 2002-12-06 Prospective identification and characterization of breast cancer stem cells
EP02799914A EP1461023A4 (fr) 2001-12-07 2002-12-06 Identification et caracterisation prospectives des cellules souches cancereuses du sein
CA002469204A CA2469204A1 (fr) 2001-12-07 2002-12-06 Identification et caracterisation prospectives des cellules souches cancereuses du sein
JP2003551505A JP2005511754A (ja) 2001-12-07 2002-12-06 乳癌幹細胞の予測的同定および特徴づけ
US11/607,780 US7754206B2 (en) 2000-08-03 2006-12-01 Method for treating cancer using a Notch4 ligand antagonist
US11/651,214 US20090004205A1 (en) 2000-08-03 2007-01-09 Prospective identification and characterization of breast cancer stem cells
US12/758,540 US20110033481A1 (en) 2000-08-03 2010-04-12 Prospective identification and characterization of breast cancer stem cells
US13/563,884 US20120295350A1 (en) 2000-08-03 2012-08-01 Prospective Identification and Characterization of Breast Cancer Stem Cells
US13/795,381 US9089556B2 (en) 2000-08-03 2013-03-12 Method for treating cancer using an antibody that inhibits notch4 signaling

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33835801P 2001-12-07 2001-12-07
US60/338,358 2001-12-07

Related Child Applications (3)

Application Number Title Priority Date Filing Date
US10497791 A-371-Of-International 2002-12-06
US10/497,791 A-371-Of-International US20050089518A1 (en) 2000-08-03 2002-12-06 Prospective identification and characterization of breast cancer stem cells
US11/607,780 Continuation-In-Part US7754206B2 (en) 2000-08-03 2006-12-01 Method for treating cancer using a Notch4 ligand antagonist

Publications (3)

Publication Number Publication Date
WO2003050502A2 WO2003050502A2 (fr) 2003-06-19
WO2003050502A3 true WO2003050502A3 (fr) 2004-02-12
WO2003050502A9 WO2003050502A9 (fr) 2004-05-06

Family

ID=23324500

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2002/039191 WO2003050502A2 (fr) 2000-08-03 2002-12-06 Identification et caracterisation prospectives des cellules souches cancereuses du sein

Country Status (6)

Country Link
US (1) US20050089518A1 (fr)
EP (1) EP1461023A4 (fr)
JP (1) JP2005511754A (fr)
AU (1) AU2002364537A1 (fr)
CA (1) CA2469204A1 (fr)
WO (1) WO2003050502A2 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9492538B2 (en) 2000-08-03 2016-11-15 The Regents Of The University Of Michigan Isolation and use of solid tumor stem cells

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8044259B2 (en) * 2000-08-03 2011-10-25 The Regents Of The University Of Michigan Determining the capability of a test compound to affect solid tumor stem cells
CA2528669A1 (fr) 2003-06-09 2005-01-20 The Regents Of The University Of Michigan Compositions et methodes de traitement et de diagnostic du cancer
ES2383306T3 (es) * 2004-02-03 2012-06-20 The Regents Of The University Of Michigan Composiciones para el tratamiento del cáncer de mama y de páncreas
WO2005074633A2 (fr) 2004-02-03 2005-08-18 The Regents Of The University Of Michigan Compositions et procédés permettant de caractériser, de réguler, de diagnostiquer et de traiter des cancers
EP1732549A4 (fr) * 2004-03-18 2009-11-11 Brigham & Womens Hospital Procedes pour le traitement de synucleinopathies
US20070293539A1 (en) * 2004-03-18 2007-12-20 Lansbury Peter T Methods for the treatment of synucleinopathies
CA2559221A1 (fr) * 2004-03-18 2005-09-29 Brigham And Women's Hospital, Inc. Procedes pour le traitement de synucleinopathies
US20050277629A1 (en) * 2004-03-18 2005-12-15 The Brigham And Women's Hospital, Inc. Methods for the treatment of synucleinopathies (Lansbury)
GB0406215D0 (en) 2004-03-19 2004-04-21 Procure Therapeutics Ltd Prostate stem cell
US8048418B2 (en) 2004-10-29 2011-11-01 Regeneron Pharmaceuticals, Inc. Therapeutic methods for inhibiting tumor growth with combination of Dll4 antagonists and VEGF antagonists
JP2006349658A (ja) * 2005-02-21 2006-12-28 Hisamitsu Pharmaceut Co Inc 神経系癌幹細胞の検出試薬、神経系癌幹細胞を分離する方法、神経系癌幹細胞、及び神経芽腫の予後診断薬。
KR100868316B1 (ko) * 2005-04-20 2008-11-11 재단법인서울대학교산학협력재단 유방 조직에서 유래된 줄기 세포, 이의 제조방법 및이로부터 분화된 세포
EP1907858A4 (fr) 2005-06-13 2009-04-08 Univ Michigan Compositions et procedes de traitement et de diagnostic du cancer
JP5405824B2 (ja) * 2005-06-30 2014-02-05 ホワイトヘッド インスティチュート フォー バイオメディカル リサーチ 前駆細胞及びその使用
US20070220621A1 (en) * 2005-10-31 2007-09-20 Clarke Michael F Genetic characterization and prognostic significance of cancer stem cells in cancer
AU2006344359B2 (en) 2005-10-31 2013-08-15 Oncomed Pharmaceuticals, Inc. Compositions and methods for diagnosing and treating cancer
US7723477B2 (en) 2005-10-31 2010-05-25 Oncomed Pharmaceuticals, Inc. Compositions and methods for inhibiting Wnt-dependent solid tumor cell growth
AU2006308847C1 (en) 2005-10-31 2012-05-10 Oncomed Pharmaceuticals, Inc. Compositions and methods for treating and diagnosing cancer
CA2630839C (fr) * 2005-12-16 2017-01-17 Regeneron Pharmaceuticals, Inc. Procedes therapeutiques pour l'inhibition de croissance tumorale avec des antagonistes dll4
WO2008121102A2 (fr) * 2006-02-21 2008-10-09 The Regents Of The University Of Michigan Traitement du cancer par un antagoniste de la voie de signalisation hedgehog
US20070243192A1 (en) * 2006-02-21 2007-10-18 Regents Of The University Of Michigan Growth hormone receptor antagonist cancer treatment
WO2007109193A2 (fr) * 2006-03-16 2007-09-27 Health Research Inc. Inhibition de la croissance et de la métastase de cellules souches du cancer du sein
WO2007142987A2 (fr) * 2006-05-30 2007-12-13 Wisconsin Alumni Research Foundation Marqueur de cellules souches mammaires
JP2009539403A (ja) 2006-06-13 2009-11-19 オンコメッド ファーマシューティカルズ インコーポレイテッド 癌を診断および処置するための組成物および方法
EP2783700A1 (fr) * 2006-09-07 2014-10-01 Stemline Therapeutics, Inc. Thérapie du cancer ciblant des cellules souches cancéreuses
JP2010502210A (ja) * 2006-09-07 2010-01-28 ウニベルシダド・デ・サラマンカ 遺伝子マーカーを使用する癌幹細胞の同定
US20080187938A1 (en) 2006-09-22 2008-08-07 The Regents Of The University Of Michigan ALDH1 As A Cancer Stem Cell Marker
BRPI0717431A2 (pt) * 2006-09-29 2013-11-12 Oncomed Pharm Inc Composições e métodos de diagnóstico e tratamento do câncer
JP5618544B2 (ja) 2007-01-24 2014-11-05 オンコメッドファーマシューティカルズ インコーポレイテッド 癌の診断および処置のための組成物および方法
EP2106439B1 (fr) 2007-01-24 2014-11-12 The Regents of the University of Michigan Compositions et procédés pour le traitement et le diagnostic du cancer du pancréas
US8158757B2 (en) 2007-07-02 2012-04-17 Oncomed Pharmaceuticals, Inc. Compositions and methods for treating and diagnosing cancer
KR20090089120A (ko) * 2008-02-18 2009-08-21 재단법인서울대학교산학협력재단 다능성 암 줄기 세포주 및 이의 제조방법
SI2307051T1 (sl) 2008-07-08 2015-04-30 Oncomed Pharmaceuticals, Inc. Notch-vezavna sredstva in antagonisti ter postopki njihove uporabe
US9132189B2 (en) 2008-07-08 2015-09-15 Oncomed Pharmaceuticals, Inc. Notch1 binding agents and methods of use thereof
WO2010037041A2 (fr) 2008-09-26 2010-04-01 Oncomed Pharmaceuticals, Inc. Agents se liant aux récepteurs frizzled et leurs utilisations
DK2356462T3 (en) 2008-11-11 2017-02-27 Univ Michigan Regents ANTI-CXCR1 COMPOSITIONS AND PROCEDURES
ES2895226T3 (es) 2009-10-16 2022-02-18 Mereo Biopharma 5 Inc Combinación terapéutica y uso de anticuerpos antagonistas de DLL4 y agentes antihipertensivos
US8945569B2 (en) 2009-11-19 2015-02-03 Oncomed Pharmaceuticals, Inc. Jagged-binding agents and uses thereof
JP2013512278A (ja) * 2009-12-01 2013-04-11 オンコメッド ファーマシューティカルズ インコーポレイテッド Ｋ−ｒａｓ変異を含んだ癌を処置するための方法
TWI535445B (zh) 2010-01-12 2016-06-01 安可美德藥物股份有限公司 Ｗｎｔ拮抗劑及治療和篩選方法
WO2011088215A2 (fr) 2010-01-13 2011-07-21 Oncomed Pharmaceuticals, Inc. Agents de liaison notch1 et leurs procédés d'utilisation
JP2013530929A (ja) 2010-04-01 2013-08-01 オンコメッド ファーマシューティカルズ インコーポレイテッド ｆｒｉｚｚｌｅｄ結合剤およびその使用
US8551479B2 (en) 2010-09-10 2013-10-08 Oncomed Pharmaceuticals, Inc. Methods for treating melanoma
CN106167526A (zh) 2011-07-15 2016-11-30 昂考梅德药品有限公司 Rspo结合剂和其应用
PL3485903T3 (pl) 2011-09-23 2023-06-12 Mereo Biopharma 5, Inc. Środki wiążące VEGF/DLL4 i ich zastosowania
NZ704269A (en) 2012-07-13 2016-05-27 Oncomed Pharm Inc Rspo3 binding agents and uses thereof
JP2015536933A (ja) 2012-10-23 2015-12-24 オンコメッド ファーマシューティカルズ インコーポレイテッド Ｗｎｔ経路結合剤を用いて神経内分泌腫瘍を処置する方法
JP6371294B2 (ja) 2012-10-31 2018-08-08 オンコメッド ファーマシューティカルズ インコーポレイテッド Ｄｌｌ４アンタゴニストによる処置の方法およびモニタリング
AU2014212081A1 (en) 2013-02-04 2015-08-13 Oncomed Pharmaceuticals, Inc. Methods and monitoring of treatment with a Wnt pathway inhibitor
US9168300B2 (en) 2013-03-14 2015-10-27 Oncomed Pharmaceuticals, Inc. MET-binding agents and uses thereof
JP2017528523A (ja) 2014-09-16 2017-09-28 オンコメッド ファーマシューティカルズ インコーポレイテッド 線維性疾患の治療
CN107530419B (zh) 2014-10-31 2021-05-18 昂考梅德药品有限公司 治疗疾病的组合疗法
AR104250A1 (es) * 2015-04-16 2017-07-05 Eisai R&D Man Co Ltd Anticuerpo anti-notch4 humano
ES2968074T3 (es) 2015-09-23 2024-05-07 Mereo Biopharma 5 Inc Anticuerpo bi-específico anti-VEGF/DLL4 para su uso en el tratamiento del cáncer de ovario resistente al platino
CA3102264A1 (fr) 2018-06-19 2019-12-26 Lunella Biotech, Inc. Cellules souches cancereuses « energetiques » (e-csc) : un nouveau phenotype de cellule tumorale hyper-metabolique et proliferative, mu par l'energie mitochondriale

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6379925B1 (en) * 1997-06-18 2002-04-30 The Trustees Of Columbia University In The City Of New York Angiogenic modulation by notch signal transduction

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4411990A (en) * 1979-06-13 1983-10-25 University Patents, Inc. Primary bioassay of human tumor stem cells
US5087570A (en) * 1988-05-10 1992-02-11 Weissman Irving L Homogeneous mammalian hematopoietic stem cell composition
US5994617A (en) * 1988-09-19 1999-11-30 Hsc Research Development Corporation Engraftment of immune-deficient mice with human cells
US5061620A (en) * 1990-03-30 1991-10-29 Systemix, Inc. Human hematopoietic stem cell
IL101728A (en) * 1991-05-03 2007-08-19 Univ Yale Human Abandonment and Delta, Restrictive Areas of Effect in Tophoric Proteins, and Methods Based on Them
IE20030749A1 (en) * 1991-05-03 2003-11-12 Indiana University Foundation Human notch and delta binding domains in torporythmic proteins, and methods based thereon
US5856441A (en) * 1991-05-03 1999-01-05 Yale University Serrate fragments and derivatives
US5750376A (en) * 1991-07-08 1998-05-12 Neurospheres Holdings Ltd. In vitro growth and proliferation of genetically modified multipotent neural stem cells and their progeny
US5851832A (en) * 1991-07-08 1998-12-22 Neurospheres, Ltd. In vitro growth and proliferation of multipotent neural stem cells and their progeny
US6353150B1 (en) * 1991-11-22 2002-03-05 Hsc Research And Development Limited Partnership Chimeric mammals with human hematopoietic cells
US5869282A (en) * 1991-12-11 1999-02-09 Imperial Cancer Research Technology, Ltd. Nucleotide and protein sequences of the serrate gene and methods based thereon
US6004924A (en) * 1991-12-11 1999-12-21 Imperial Cancer Research Technology, Ltd. Protein sequences of serrate gene products
US5786158A (en) * 1992-04-30 1998-07-28 Yale University Therapeutic and diagnostic methods and compositions based on notch proteins and nucleic acids
US5928947A (en) * 1992-07-27 1999-07-27 California Institute Of Technology Mammalian multipotent neural stem cells
US5589376A (en) * 1992-07-27 1996-12-31 California Institute Of Technology Mammalian neural crest stem cells
US5849553A (en) * 1992-07-27 1998-12-15 California Institute Of Technology Mammalian multipotent neural stem cells
AU678988B2 (en) * 1992-07-27 1997-06-19 California Institute Of Technology Mammalian multipotent neural stem cells
US5654183A (en) * 1992-07-27 1997-08-05 California Institute Of Technology Genetically engineered mammalian neural crest stem cells
US5650317A (en) * 1994-09-16 1997-07-22 Michigan State University Human breast epithelial cell type with stem cell and luminal epithelial cell characteristics
US5736396A (en) * 1995-01-24 1998-04-07 Case Western Reserve University Lineage-directed induction of human mesenchymal stem cell differentiation
US5821108A (en) * 1995-04-07 1998-10-13 The Board Of Trustees Of The Leland Stanford Junior University Enrichment for a thymocyte subset having progenitor cell activity using c-kit as a selection marker
US5780300A (en) * 1995-09-29 1998-07-14 Yale University Manipulation of non-terminally differentiated cells using the notch pathway
US5753506A (en) * 1996-05-23 1998-05-19 Cns Stem Cell Technology, Inc. Isolation propagation and directed differentiation of stem cells from embryonic and adult central nervous system of mammals
CA2263883C (fr) * 1996-08-29 2003-07-08 The Regents Of The University Of California Kuz, nouvelle famille de metalloproteases
WO1998057621A1 (fr) * 1997-06-18 1998-12-23 The Trustees Of Columbia University In The City Ofnew York Modulation angiogenique par transduction du signal de notch
US6136952A (en) * 1997-06-25 2000-10-24 University Of Washington Human jagged polypeptide, encoding nucleic acids and methods of use
US6004528A (en) * 1997-09-18 1999-12-21 Bergstein; Ivan Methods of cancer diagnosis and therapy targeted against the cancer stemline
US6197523B1 (en) * 1997-11-24 2001-03-06 Robert A. Levine Method for the detection, identification, enumeration and confirmation of circulating cancer and/or hematologic progenitor cells in whole blood
US6380362B1 (en) * 1999-12-23 2002-04-30 Genesis Research & Development Corporation Ltd. Polynucleotides, polypeptides expressed by the polynucleotides and methods for their use
US6984522B2 (en) * 2000-08-03 2006-01-10 Regents Of The University Of Michigan Isolation and use of solid tumor stem cells
US20020151487A1 (en) * 2000-08-31 2002-10-17 Loyola University Chicago Method and reagents for epithelial barrier formation and treatment of malignant and benign skin disorders by modulating the notch pathway
EP2388330B1 (fr) * 2001-06-22 2015-05-20 StemCells, Inc. Cellules de greffe hépatique, dosages, et leurs utilisations

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6379925B1 (en) * 1997-06-18 2002-04-30 The Trustees Of Columbia University In The City Of New York Angiogenic modulation by notch signal transduction

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CALLAHAN R. ET AL.: "Notch signaling in mammary gland tumorigenesis", JOURNAL OF MAMMARY GLAND BIOLOGY AND NEOPLASIA, vol. 6, no. 1, January 2001 (2001-01-01), pages 23 - 36, XP001094918 *
HENNIGHAUSEN L.: "Mouse models for breast cancer", ONCOGENE, vol. 19, 2000, pages 966 - 967, XP002973794 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9492538B2 (en) 2000-08-03 2016-11-15 The Regents Of The University Of Michigan Isolation and use of solid tumor stem cells

Also Published As

Publication number Publication date
WO2003050502A2 (fr) 2003-06-19
JP2005511754A (ja) 2005-04-28
CA2469204A1 (fr) 2003-06-19
US20050089518A1 (en) 2005-04-28
WO2003050502A9 (fr) 2004-05-06
EP1461023A2 (fr) 2004-09-29
AU2002364537A1 (en) 2003-06-23
EP1461023A4 (fr) 2005-08-31

Similar Documents

Publication Publication Date Title
WO2003050502A3 (fr) Identification et caracterisation prospectives des cellules souches cancereuses du sein
Bang et al. Terminal neuroendocrine differentiation of human prostate carcinoma cells in response to increased intracellular cyclic AMP.
Manchester et al. An extinct genus with affinities to extant Davidia and Camptotheca (Cornales) from the Paleocene of North America and eastern Asia
ATE359338T1 (de) Gesintertes, polykristallines zirkonia enthaltende schleifteilchen
HK1068913A1 (en) Antigen presenting cells, method for their preparation and their use for cancer vaccines
Dalton et al. Preservational and morphological variability of assemblages of agglutinated eukaryotes in Cryogenian cap carbonates of northern Namibia
IL180612A0 (en) Materials and methods for immune system stimulation
Skovsted et al. The tommotiid Camenella reticulosa from the early Cambrian of South Australia: morphology, scleritome reconstruction, and phylogeny
Garavello et al. The cascudos of the genus Hypostomus Lacépède (Ostariophysi: Loricariidae) from the rio Iguaçu basin
Skelton Part N, Volume 1, Chapter 26A: Introduction to the Hippuritida (rudists): Shell structure, anatomy, and evolution
Rasetti New Upper Cambrian trilobites from the Lévis conglomerate
Mindell et al. Anatomically preserved staminate inflorescences of Gynoplatananthus oysterbayensis gen. et sp. nov.(Platanaceae) and associated pistillate fructifications from the Eocene of Vancouver Island, British Columbia
WO2002072021A3 (fr) Agents et procedes pour la prevention de l'apparition initiale ou de la recurrence des cancers existants
Blake Paralbula, a new fossil fish based on dental plates from the Eocene and Miocene of Maryland
AU2001233912A1 (en) Diagnosis of breast cancer using bcmp-81 as marker
US2117736A (en) Gem setting
Sprinkle et al. New edrioasterine and astrocystitid (Echinodermata: Edrioasteroidea) from the Ninemile Shale (Lower Ordovician), central Nevada
Turrisi Revision of the Afrotropical species of Pristaulacus Kieffer, 1900 (Hymenoptera: Aulacidae)
Rakotonirina et al. Revision of the Pachycondyla sikorae species-group (Hymenoptera: Formicidae) in Madagascar
CA2294158A1 (fr) Substances naturelles antitumorales ou antivirales et leur utilisation
Yoon et al. Medieval Coins from the Site of San Vincenzo on the Island of Stromboli, Italy
Knudsen et al. Lecanora annularis (Lecanoraceae, Lecanorales), a new lichen species from the Channel Islands and the Central California Coast
Kirk Four new genera of camerate crinoids from the Devonian [North America, France, and Spain]
CN206380818U (zh) 一种车花片式宝石座及具有该宝石座的戒指
Kessler et al. New species of grammitid ferns (Polypodiaceae, Polypodiopsida) from Bolivia

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
COP Corrected version of pamphlet

Free format text: PAGES 30-37, CLAIMS, REPLACED BY NEW PAGES 30-37; AFTER RECTIFICATION OF OBVIOUS ERRORS AUTHORIZED BY THE INTERNATIONAL SEARCH AUTHORITY

WWE Wipo information: entry into national phase

Ref document number: 2469204

Country of ref document: CA

Ref document number: 2003551505

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2002364537

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2002799914

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2002799914

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 10497791

Country of ref document: US

WWW Wipo information: withdrawn in national office

Ref document number: 2002799914

Country of ref document: EP